Evidence map›Paper›PMID 29780110›Full record

ArticleInternal medicine (Tokyo, Japan)2018

Bevacizumab-induced Aortic Arterial Thrombosis.

Kazuo Suzuki, Takahiro Yanagimura, Kazumasa Ohashi, Hiroshi Kagamu, Toshinori Takada

Open access · diamondAbstract readCase Reports
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Vascular toxic effects of cancer therapies.Nature reviews. Cardiology · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Kazuo SuzukiDepartment of Internal Medicine, Niigata Prefectural Matsudai Hospital, Japan.
Takahiro YanagimuraDepartment of Respiratory and Infectious Medicine, Uonuma Kikan Hospital, Niigata University Medical and Dental Hospital, Japan.
Kazumasa OhashiDepartment of Respiratory and Infectious Medicine, Uonuma Kikan Hospital, Niigata University Medical and Dental Hospital, Japan.
Hiroshi KagamuDepartment of Respiratory Medicine, Saitama Medical University International Medical Center, Japan.
Toshinori TakadaDepartment of Respiratory and Infectious Medicine, Uonuma Kikan Hospital, Niigata University Medical and Dental Hospital, Japan.
Niigata University Medical and Dental Hospital · JPSaitama Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 65-year-old man was diagnosed with advanced non-small, non-squamous lung cancer. He was treated with chemotherapy containing bevacizumab as well as cisplatin and pemetrexed. After 2 courses of treatment, computed tomography revealed that his abdominal aortic artery was almost occluded by a thrombus; however, he had no ischemic symptoms. Heparin infusion and warfarin reduced the size of the arterial thrombus and the patient was subsequently treated with chemotherapy without bevacizumab. No thrombotic events occurred during the subsequent treatment. We later noticed a small organized abdominal arterial clot and calcification on a computed tomography scan taken before bevacizumab treatment. Atherosclerotic changes should be evaluated before the administration of bevacizumab.

Indexed as

AgedAntineoplastic Combined Chemotherapy ProtocolsAortic DiseasesBevacizumabCarcinoma, Non-Small-Cell LungCisplatinHeparinHumansLung NeoplasmsMalePemetrexedThrombosisTreatment OutcomeWarfarinBevacizumabCisplatinHeparinPemetrexedWarfarinarterial thrombosisbevacizumabnon-smallnon-squamous lung cancer

Identifiers

PMID29780110
PMCPMC6232032
OpenAlexW2804915995

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.